Clearmind Medicine Inc., a clinical-stage biotech company, has announced the expansion of its ongoing Phase I/IIa clinical trial for the treatment of Alcohol Use Disorder (AUD) with the inclusion of Tel Aviv Sourasky Medical Center in Israel. The trial is evaluating CMND-100, a proprietary MEAI-based oral drug candidate. The enrollment of the first patient was completed earlier this month. The study at Tel Aviv Sourasky Medical Center will be led by Dr. David Zeltser. This expansion includes other prestigious institutions such as Yale School of Medicine and Johns Hopkins University School of Medicine. The trial aims to evaluate the safety, tolerability, and pharmacokinetic profile of CMND-100, while exploring its potential to reduce alcohol cravings and consumption in patients with AUD. Results from the trial have not yet been presented.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。